News
SDZNY
73.14
+0.52%
0.38
Weekly Report: what happened at SDZNY last week (1222-1226)?
Weekly Report · 12/29/2025 09:47
Weekly Report: what happened at SDZNY last week (1215-1219)?
Weekly Report · 12/22/2025 09:47
SDZNY vs. STVN: Which Stock Is the Better Value Option?
NASDAQ · 12/19/2025 16:40
Sandoz initiated with a Neutral at Oddo BHF
TipRanks · 12/18/2025 17:50
Weekly Report: what happened at SDZNY last week (1208-1212)?
Weekly Report · 12/15/2025 09:52
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
NASDAQ · 12/09/2025 09:53
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
NASDAQ · 12/08/2025 13:23
Evotec Closed Its Previously Reported Sale Of The Just-evotec Biologics Toulouse Site Plus An Indefinite Technology License To Its Continuous Manufacturing Platform Technology To Sandoz, Potential Payments Of Over $650M Plus Royalties Of Up To 10 Biosimilar Molecules
Benzinga · 12/08/2025 10:51
Weekly Report: what happened at SDZNY last week (1201-1205)?
Weekly Report · 12/08/2025 09:51
Sandoz Completes Acquisition Of Just-Evotec Biologics
NASDAQ · 12/08/2025 06:40
Evotec Closes Sale of Toulouse Biologics Site and Technology License to Sandoz
Reuters · 12/08/2025 06:03
Sandoz Completes Acquisition of Just-Evotec Biologics EU SAS
Reuters · 12/08/2025 06:02
Mark Cuban calls for end to generic drug application fees to boost domestic manufacturing
Seeking Alpha · 12/04/2025 14:24
Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Buy: Here's Why
NASDAQ · 12/03/2025 17:00
Morgan Stanley Reaffirms Their Hold Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 12/03/2025 07:35
Weekly Report: what happened at SDZNY last week (1124-1128)?
Weekly Report · 12/01/2025 09:48
Sandoz Launches Denosumab Biosimilars in Europe
Reuters · 12/01/2025 06:02
Weekly Report: what happened at SDZNY last week (1117-1121)?
Weekly Report · 11/24/2025 09:52
Sandoz Wins European Commission Approval for Afqlir Biosimilar Aflibercept
Reuters · 11/24/2025 06:21
PRESS DIGEST-Canada - Nov 21
Reuters · 11/21/2025 13:49
More
Webull provides a variety of real-time SDZNY stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZNY
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.